Moderna mRNA flu vaccine unanimously recommended by VRBPAC; HHS claims ACIP cannot meet for flu season; adjuvanted flu modeling for 50-64; practical guidance not to wait
Key Questions
What was VRBPAC's recommendation on Moderna's mRNA flu vaccine?
On June 18, VRBPAC unanimously recommended mFlusiva for adults 50+ (full approval) and 65+ (accelerated). The FDA is expected to issue a final decision on August 5.
Why might adults 50+ consider waiting for the new mRNA flu shot?
The vaccine showed no serious safety concerns in review and offers potential benefit for older adults. Canada already recommends enhanced vaccines for seniors, and U.S. modeling supports use in ages 50-64.
What operational challenges exist for the 2026-2027 flu season?
HHS stated ACIP cannot meet in time for flu season, creating access risks for pharmacies and patients. New data show flu vaccination reduces mortality by 29% in older adults.
VRBPAC June 18 unanimously recommended Moderna's mRNA flu vaccine (mFlusiva) for older adults (50+ full, 65+ accelerated). Final FDA decision Aug 5. Canada recommends enhanced vaccines for seniors 65+. New study: flu vaccine reduces mortality by 29% in older adults. HHS claims ACIP cannot meet for flu season; operational risk for pharmacy and patient access. Moderna's mRNA flu vaccine review shows no serious concerns. New adjuvanted flu vaccine modeling for ages 50-64 suggests potential benefit, supporting enhanced vaccine use in this age group. New practical guidance: adults 50+ should not wait for the mRNA flu shot; current vaccines are effective and available now.